Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
Wave Life Sciences (WVE), a clinical-stage biotech company specializing in RNA medicines, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on June 4, 2025, at 4:55 p.m. ET in New York City. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for a limited time afterward.
Wave Life Sciences (WVE), un'azienda biotecnologica in fase clinica specializzata in terapie a base di RNA, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025. Il Presidente e CEO della società, Paul Bolno, MD, MBA, prenderà parte a una conversazione informale guidata da analisti il 4 giugno 2025 alle 16:55 ET a New York. La presentazione sarà disponibile in diretta streaming sul sito web delle relazioni con gli investitori dell'azienda, con una replica accessibile per un periodo limitato successivamente.
Wave Life Sciences (WVE), una empresa biotecnológica en etapa clínica especializada en medicamentos de ARN, ha anunciado su participación en la Conferencia Global de Salud Jefferies 2025. El presidente y CEO de la compañía, Paul Bolno, MD, MBA, participará en una charla junto a analistas el 4 de junio de 2025 a las 4:55 p.m. ET en la ciudad de Nueva York. La presentación será accesible mediante una transmisión en vivo a través del sitio web de relaciones con inversionistas de la empresa, con una repetición disponible por tiempo limitado después.
Wave Life Sciences (WVE)는 RNA 의약품을 전문으로 하는 임상 단계의 바이오테크 회사로, 2025년 제프리스 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Paul Bolno, MD, MBA가 2025년 6월 4일 오후 4시 55분(동부 표준시) 뉴욕시에서 애널리스트 주도 대담에 참여할 예정입니다. 발표는 회사 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 제공되며, 이후 제한된 기간 동안 다시보기로도 이용할 수 있습니다.
Wave Life Sciences (WVE), une société biotechnologique en phase clinique spécialisée dans les médicaments à base d'ARN, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025. Le président et CEO de l'entreprise, Paul Bolno, MD, MBA, participera à une discussion animée par des analystes le 4 juin 2025 à 16h55 ET à New York. La présentation sera accessible en direct via un webcast sur le site des relations investisseurs de la société, avec une rediffusion disponible pendant une durée limitée par la suite.
Wave Life Sciences (WVE), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf RNA-Medikamente spezialisiert hat, hat seine Teilnahme an der Jefferies Global Healthcare Conference 2025 angekündigt. Der Präsident und CEO des Unternehmens, Paul Bolno, MD, MBA, wird an einem von Analysten geführten Gespräch am 4. Juni 2025 um 16:55 Uhr ET in New York City teilnehmen. Die Präsentation wird als Live-Webcast über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einer anschließenden zeitlich begrenzten Wiederholung.
- None.
- None.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET.
A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
InvestorRelations@wavelifesci.com
Media:
MediaRelations@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) presenting at the 2025 Jefferies Healthcare Conference?
Who will represent Wave Life Sciences (WVE) at the 2025 Jefferies Healthcare Conference?
How can investors watch Wave Life Sciences' (WVE) presentation at the Jefferies Conference?
What is Wave Life Sciences' (WVE) main business focus?
